Nektar Announces Positive Phase 1b Data For NKTR-358 In Patients With Atopic Dermatitis
15/12 15:44
(RTTNews) - Nektar Therapeutics (NKTR) said that proof-of-concept data presented by its partner Eli Lilly & Co. showed that, in patients with moderate to severe atopic dermatitis, NKTR-358 (LY3471851) given every two weeks over a 12-week period resulted in a dose-dependent reduct...